ClinicalTrials.gg
Enrolling by invitationNCT04643262PSICHEUpdated Jul 21, 2021

Sleeve Gastrectomy: Outcome, Morbidity and Mortality. A Multicentric Retrospective Trial

An observational study in Morbid Obesity, sponsored by Azienda Sanitaria Locale Napoli 2 Nord. Enrolling by invitation. Open to participants aged 18 Years to 68 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-21.

Sponsored by Azienda Sanitaria Locale Napoli 2 Nord · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10,000
Ages
18 Years to 68 Years
Sex
All
01

Study summary

Laparoscopic sleeve gastrectomy (LSG) is currently the most frequent primary bariatric procedure performed worldwide. LSG is a safe and effective technique in terms of excess weight loss and it is, moreover, a powerful metabolic operation that activates significant hormonal pathways that lead to changes in eating behavior, glycemic control and intestinal functions.Regarding a technical point of view, LSG might be considered a time saving procedure for the absence of intestinal anastomosis. The most frequent and sometimes dangerous complications are leaking, hemorrhage, splenic injury, stenosis and Gastro-Esophageal Reflux Disease (GERD). Despite its established efficacy and safety, dispute still exists on the optimal conduction of LSG operative technique: bougie size, distance of resection margin from the pylorus, the shape of section at the gastroesophageal junction, staple line reinforcement and intraoperative leak testing are among the most controversial issues .

Thus, the primary aim of the present retrospective multicentric study is to evaluate intra and peri-operatory (\< 30 days) and post-operative (> 30 days) morbidity and mortality rates of patients undergone LSG, and the correlation of the latter rates with different surgical measures. Secondary aim is to evaluate the strategy for the treatment of the complication, and if there is a correlation between morbidity/mortality and volume of the Bariatric Center

Read the detailed description

This study is a retrospective multicenter trial conduct from January 2015 to December 2020 in 10 centers. All the procedures were performed by the (---- number of surgeons). Morbid obesity was preoperatively diagnosed according to the International Federation for Surgery of Obesity (IFSO) guidelines. Patients were collected in a electronic database and categorized according to the following parameters:

  • Distance of resection margin from the pylorus (>5 cm / \<5 cm)
  • Bougie size (>34 French, \<34 French)
  • Distance of resection margin from the gastroesophageal junction (>...cm/\<...cm)
  • Staple line reinforcement (Yes/No - If yes, the reinforcement technique will be reported)
  • Intraoperative leak testing (Yes/No - If yes, the test used will be reported)
  • Number and size of trocar used and access closure technique (Yes/No - If yes, the technique will be reported) The study protocol was approved by the regional Ethics Committee. 2.2 Inclusion criteria Inclusion criteria were morbid obesity defined as BMI 40 kg/m2 or BMI>35 with comorbidity and age between 25-60 years old. Obesity-related comorbidities included Type 2 Mellitus Diabetes (T2MD), hypertension, hyperlipidemia, bronchial asthma, osteoarthritis and degenerative joint disease.

2.3 Exclusion Criteria Patients with endocrine disorders causing obesity (as hypothyroidism and Cushing disease), pregnancy or lactation, psychiatric illness, or recent diagnosis of malignancy, inflammatory bowel disease, Barrett ́s esophagus, and GERD with esophagitis scored as or greater than grade B, a large hiatal hernia (>3 cm) were excluded from the study.

2.4 Study Outcomes The primary aims of the present retrospective multicentric study is to evaluate intra and peri and post operatory morbidity and mortality rates (\< 30 and >30 days) of patients undergone Laparoscopic Sleeve Gastrectomy, and the correlation of the latter rates with different surgical measures. Secondary aims is to evaluate the strategy for the treatment of the complication, and if there is a correlation between morbidity/mortality and the volume of the Bariatric Center.

2.6 Blinding Process Physicians and staff who will collect the data and those who will evaluate the endpoints will all be unaware of the patients allocation. Patients will be collected in an electronic database with consecutive numbers without the possibility of identifying the center of origin until the final evaluation of the study endpoints. As the blinding process for the operating surgeons is not feasible, they are not involved in data collection and evaluation of results.

2.5 Pre-operative evaluation Preoperative evaluation included anthropometric measurements (height in cm, weight in kg, Body Mass Index (BMI) in kg/m2), comorbidity evaluation [Glycated Hemoglobin(A1c), C-peptide, stimulated C-peptide, Electrocardiography (ECG), echocardiography, lower limbs US color-doppler study, thyroid function profile]. All patients were evaluated for the presence/absence of Gastro Esophageal Reflux Disease before surgery through a preoperative upper endoscopy with an eventual esophageal biopsy. The presence of helicobacter pylori is also investigated with for a rapid urease test on an antral specimen.

2.7 Surgical Technique The patient is placed in a split leg position with the surgeon located in between the patient's legs. Closed pneumoperitoneum was established using our standard technique of Verres needle insufflation in Palmer site and optical insertion of a 12-mm port at a supraumbilical site (10-15 cm from umbilicus) Two further 15-mm and 12-mm ports were placed respectively in the left and right ipocondrum as working ports. A subxiphoid track was created using a 5-mm port for placement of a liver retractor. In patients with higher body mass index who have severe visceral obesity, additional trocars can be added for retraction of the omentum or big fatty livers, to optimize the exposure to reach the left crus. Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. Researchers use a 36French bougie or --------- Researchers have chosen cartridges Black at the antrum level and finished with a purple cartridge. Researchers always checked the posterior wall before firing. Once Researchers have reached the proximal stomach, the stapler has to be positioned 1 cm lateral to the left of the angle of His to avoid inclusion of esophageal tissue. Methylene blue test is performed routinely.

2.8 Post-operative evaluation Regarding the primary endpoints, intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded. Perioperative complications (\<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment. Postoperative complications (>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment Regarding the secondary endpoint, in case of gastric fistula onset its diagnosis method (clinical, instrumental) and its management (timing, surgical or endoscopic - endoprosthesis, pigtails, clips-) or both) are collected and recorded. In case of postoperative bleeding, its diagnosis method (clinical, instrumental) and its management (timing, Surgical, medical) are collected and recorded.

3.6 Statistical Analysis Continuous data are expressed as median and interquartile (25-75th) range or mean and Standard Deviation (SD), unless otherwise indicated. Differences between preoperative and postoperative parameters were compared by Wilcoxon paired rank test. Median time of follow-up was estimated using the Kaplan-Meier method. Multivariable analysis was conducted through a forward-backward stepwise Cox regression based on Akaike Information Criterion (AIC) considering age, gender, % Excess Weighth Loss, Body Mass Index and treatment.

For all tests, the cut-off for statistical significance was set at p= 0.05. Statistical analysis was performed using R v3.5.0.

02

Conditions studied

  • Morbid Obesity

Browse trials for

Keywords

  • Bariatric surgery
  • morbidity and mortality
03

In context

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Azienda Sanitaria Locale Napoli 2 Nord is the lead sponsor of 16 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study is a retrospective multicenter trial conduct from January 2015 to December 2020 in 20 centers. All patients underwent Sleeve Gastrectomy. All the procedures were performed by the (---- number of surgeons). Morbid obesity was preoperatively diagnosed according to the International Federation for Surgery of Obesity (IFSO) guidelines

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Morbid obesity defined as 40 kg/m2
  • Body Mass Index >35 with comorbidity (Type 2 Mellitus Diabetes (T2MD), hypertension, hyperlipidemia, bronchial asthma, osteoarthritis))
  • Age between 25-68 years old.

Exclusion criteria

Exclusion Criteria:

  • Patients with endocrine disorders causing obesity (as hypothyroidism and Cushing disease)
  • Pregnancy or lactation
  • Psychiatric illness
  • Recent diagnosis of
  • Inflammatory bowel disease
  • Barrett ́s esophagus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intraoperative morbidity and mortality

    Intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded.

    Procedure: Sleeve Gastrectomy

  • peri-operative morbidity and mortality (<30 days)

    Perioperative complications (\<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment.

    Procedure: Sleeve Gastrectomy

  • Post-operative morbidity and mortality (>30 days)

    Postoperative complications (\>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment

    Procedure: Sleeve Gastrectomy

Interventions

  • ProcedureSleeve Gastrectomy

    Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.

06

What researchers measure

Primary outcomes

  1. Intraoperative complications

    splenectomy, bleeding, positive leak test if performed

    Time frame: time 0

  2. Perioperative complications

    Mortality

    Time frame: up to 4 weeks from surgery

  3. Perioperative complications

    Morbidity:( leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) \< 30 days

    Time frame: up to 4 weeks from surgery

  4. Postoperative complications

    Mortality

    Time frame: up to 6 months

  5. Postoperative complications

    Morbidity: (leak, embolism, Incisional trocar hernia) \>30 days

    Time frame: up to 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Jan 2015, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2020
First posted
Nov 25, 2020
StartActual
Jan 1, 2015
Primary completionActual
Jan 1, 2015
CompletionEst.
Jun 30, 2026
Last update
Jul 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04643262
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Responsible party
Francesco Pizza (MD,PhD, Responsible for the Bariatric and Metabolic Surgery unit, Azienda Sanitaria Locale Napoli 2 Nord) — Principal investigator
First posted
Nov 25, 2020
Start date
Jan 1, 2015
Primary completion
Jan 1, 2015
Completion
Jun 30, 2026 (estimated)
Last update
Jul 21, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion